Monopar Therapeutics (NASDAQ:MNPR) Stock Rating Lowered by Wall Street Zen

Monopar Therapeutics (NASDAQ:MNPR) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other brokerages have also recently weighed in on MNPR. Barclays reiterated an “overweight” rating and issued a $145.00 target price (up from $128.00) on shares of Monopar Therapeutics in a report on Friday, September 11th. HC Wainwright upped their price target on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a research note on Wednesday, July 22nd. Zacks Research downgraded Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Morgan Stanley restated an “overweight” rating and issued a $130.00 price objective on shares of Monopar Therapeutics in a report on Monday, August 17th. Finally, BTIG Research lifted their price objective on Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $122.00.

Monopar Therapeutics Price Performance

Shares of MNPR opened at $78.96 on Friday. The firm has a market cap of $529.82 million, a PE ratio of -36.39 and a beta of 1.50. The company’s fifty day moving average is $104.34 and its two-hundred day moving average is $83.70. Monopar Therapeutics has a fifty-two week low of $50.07 and a fifty-two week high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.02. As a group, equities research analysts anticipate that Monopar Therapeutics will post -2.98 earnings per share for the current year.

Insider Buying and Selling at Monopar Therapeutics

In other news, Director Christopher M. Starr sold 8,400 shares of the firm’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $78.50, for a total value of $659,400.00. Following the transaction, the director owned 5,173 shares of the company’s stock, valued at approximately $406,080.50. This trade represents a 61.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chandler Robinson sold 29,056 shares of the firm’s stock in a transaction on Thursday, September 24th. The shares were sold at an average price of $88.00, for a total transaction of $2,556,928.00. Following the completion of the transaction, the chief executive officer directly owned 99,267 shares in the company, valued at approximately $8,735,496. This represents a 22.64% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 44,688 shares of company stock valued at $4,023,094 in the last ninety days. Corporate insiders own 9.70% of the company’s stock.

Institutional Trading of Monopar Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd acquired a new position in shares of Monopar Therapeutics during the fourth quarter worth about $86,000. Your Advocates Ltd. LLP purchased a new stake in shares of Monopar Therapeutics in the first quarter worth about $183,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Monopar Therapeutics in the first quarter worth about $250,000. Sei Investments Co. boosted its position in shares of Monopar Therapeutics by 9.5% in the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after buying an additional 656 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Monopar Therapeutics in the fourth quarter valued at about $654,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company’s research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies.

Monopar’s portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers.